Q3 Update: The final version of the CytoCatch™ imaging system was completed and the pre-clinical validation of our technology is underway.
Hello everyone!
Hope you and yours are well.
We know that this year has been quite challenging for everyone, but in times of such uncertainty we would like to share with you some good news 😊. The last few months have been some of the most rewarding since we started this venture.
Our new crowdfunding campaign on StartEngine is officially live 🔥. We will keep you posted throughout this exciting new journey!
Another highlight of these past months was the completion of the final version of the CytoCatch™ imaging system. The CytoCatch™ imaging system is the most complex device constituting our technology. This system was specially designed to acquire high resolution micrographs of the CTCs that were previously captured by our isolation platform. It possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. All these processes, ranging from image acquisition to image analysis, are fully automated, which increases the reliability and reproducibility of the blood assay by preventing human error 😎.
Also, leveraging the collaborations that we have with local hospitals and universities, we started a pre-clinical validation of our technology using real samples from prostate cancer patients and healthy individuals. This will help us collect invaluable data that will be crucial for selling our technology as a research tool to research centers and pharmaceutical companies, and applying for the FDA clearance, which is required for our technology to be used in a clinical setting.
Finally, we are honored to be selected as a UCSF Health Hub Quarterfinalist in the New Life Sciences Diagnostic category . The UCSF Health Awards honors outstanding technologies that are radically transforming healthcare and improving patient outcomes. This event is sponsored by some of the most renowned big tech and big pharma companies, such as Eli Lilly, Genentech, Johnson and Johnson, and Astellas. Our application was selected among the 8 finalists by a panel of 300+ eminent judges that are experts in the field. This recognition further validates the importance of developing a technology for early cancer detection and monitoring the applied treatments’ effectiveness.
Of course, none of this would have been possible without your unwavering support. Thank you for putting your trust in us during our first crowdfunding campaign on Republic 🙏. We are working really hard so our technology could benefit as many patients as possible.